Yahoo Finance December 7, 2022
H1

Which data will inform more diverse clinical trials? Will healthcare influencers leave Twitter? How will engaging HCP thought leaders evolve? H1 shares its prognosis.

NEW YORK, Dec. 07, 2022 (GLOBE NEWSWIRE) — H1, the connecting force for global healthcare provider, clinical, science, and research information, today released its predictions for 2023 to help life sciences, pharmaceutical, and healthcare companies understand larger industry trends and dynamics to plan and prepare for the new year.

Access to medicine and healthcare is a basic human right. Access to the best healthcare information is also a basic human right – one that will be more important in the 21st century than ever before. When roughly one-third of all data around the world is generated...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Big Data, Clinical Trials, Provider, Social Media, Technology, Trends
Related Articles:
25 payers among Forbes' best employers for diversity
New AI drug discovery powerhouse Xaira rises with $1B in funding
AHA podcast: Peer support lessons from NYC Health + Hospitals
Women's virtual care clinic Midi Health raises $60M
IBM to acquire HashiCorp in $6.4 billion deal, reports another revenue miss

Share This Article